Detection Of Prostate Specific Antigen Research Articles

Glycan-Matchmade Multivalent Decoration of Enzyme Labels for Amplified Electrochemical Detection of Glycoproteins.

Glycoproteins are of significant value to liquid biopsy of human diseases. Herein, we present a universal electrochemical platform for the amplified detection of glycoproteins, taking advantage of the glycan-matchmade multivalent decoration of enzyme labels for the enzymatic signal amplification. Briefly, the glycan-matchmade multivalent decoration involves two steps, i.e., the site-directed decoration of the phenylboronic acid-coated gold nanoparticles (PBA-AuNPs) to the cis-diol-containing glycans of glycoproteins and the subsequent decoration of enzyme labels via the affinity cross-linking between the glycan moieties of enzyme labels and the remaining PBA groups on the PBA-AuNP cross-linkers. As the glycan matchmaking-based strategy enables the decoration of each glycoprotein with multiple enzyme labels, this electrochemical platform exhibits a high sensitivity toward glycoprotein detection. Using alkaline phosphatase (ALP) as the proof-of-concept enzyme label in combination with the solid-state voltammetric stripping assay of the enzymatically deposited metallic silver, the detection limits at the pg mL-1 level have been obtained for the electrochemical aptamer-based detection of thrombin and prostate-specific antigen. Overall, this work illustrates an efficient and versatile strategy for the multivalent decoration of enzyme labels for electrochemical detection of glycoproteins at ultralow concentration levels, holding the desirable advantages of simplicity and cost-effectiveness over sandwich enzyme-linked immunosorbent assays.

Ultrahighly sensitive sandwich-type electrochemical immunosensor for selective detection of prostate specific antigen based on functionalized bimetallic Au-Ag nanoclusters as label for signal amplification

Ultrahighly sensitive sandwich-type electrochemical immunosensor for selective detection of prostate specific antigen based on functionalized bimetallic Au-Ag nanoclusters as label for signal amplification

Label-free electrochemical immunoassay for ultra-sensitive detection of PSA utilizing gold nanoparticles/polyhedral hollow CoCu bimetallic sulfide nanostructure as a dual signal amplification platform.

This study introduces the development of a highly sensitive label-free electrochemical immunosensor specifically designed to detect prostate-specific antigen (PSA). A glassy carbon electrode (GCE) coated with Au nanoparticles/polyhedral hollow CoCu bimetallic sulfide (CuCo2S4) was employed as a sensing interface for the fixation of the monoclonal anti-PSA antibody. The nanoarchitectures enhanced the capacity for loading prostate-specific antibodies (Ab) and effectually boosted electrical conductivity leading to enhance the electrochemical signal and greater sensitivity for the detection of PSA. The electrochemical behavior of the engineered sensor was researched via cyclic voltammetry (CV), electrochemical impedance spectroscopy (EIS), and differential pulse voltammetry (DPV). The response of the fabricated immunosensor manifested a linearized correlation with PSA concentration, spanning from 50.0 fg/ml to 500.0 ng/ml, with a minimal detection limit (DPV: 19.0 fg/ml, EIS: 14.0 fg/ml) and superior stability. The morphological and structural features of the engineered nanomaterials were analyzed using a range of techniques, including field emission scanning electron microscopy (FESEM), energy dispersive X-ray analysis (EDX), X-ray diffraction (XRD), and Fourier transform infrared spectroscopy (FTIR). The proposed immunosensor was utilized for the meticulous and ultra-sensitive analysis of PSA levels in serum specimens, providing results that align satisfactorily with those from the enzyme-linked immunosorbent assay (ELISA) the benchmark protocol. In conclusion, these outcomes underscore the potential utility of the developed immunosensor for prostate cancer screening in its initial stages.

A high sensitivity prostate-specific antigen SERS detection platform based on laser resonance nanoparticles.

Accurate quantitative analysis of cancer-related specific biomarkers in clinical serum is very important for the early diagnosis and treatment of cancer. Hospitals often use serum prostate-specific antigen (PSA) as a biomarker associated with prostate cancer diagnosis and prognosis, and prostate cancer cells often produce more PSA than benign cells, leading to elevated PSA levels in the blood. In this study, an immunoassay based on surface-enhanced Raman scattering (SERS) was established for the detection of PSA employing magnetic beads along with SERS nanotags. The hospital currently takes two hours to test the results, the equipment price is high, and the detection price is high, and the penetration rate in township hospitals in China is low. SERS has super-sensitive and fast detection ability, and the availability of the detection result in 10 minutes significantly reduces the waiting time. Besides, the detection method is simple, cheap and portable, making it suitable for township health centers. To evaluate the clinical applicability of this method, 75 male clinical serum samples were tested, most of which were in the gray area of 4.0-10.0 ng mL-1. The experimental results show that our detection method has good agreement with the results measured by the electrochemical luminescence (ECL) system in the hospital clinical laboratory. Our detection limit for actual samples from patients can reach 0.029 ng mL-1. Therefore, our clinical serum PSA marker detection method based on SERS has a great potential market in towns and villages.

Flexible Memristive Biosensors for Sensitive Detection of Prostate-Specific Antigen in Biological Environments

Flexible Memristive Biosensors for Sensitive Detection of Prostate-Specific Antigen in Biological Environments

Development and Mechanistic Exploration of a Graphene Oxide-Based Fluorescent Sensor for Prostate-Specific Antigen Detection

Development and Mechanistic Exploration of a Graphene Oxide-Based Fluorescent Sensor for Prostate-Specific Antigen Detection

Lattice atom-bridged chemical bond interface facilitates charge transfer for boosted photoelectric response

ABSTRACT The construction of chemical bonds at heterojunction interfaces currently presents a promising avenue for enhancing photogenerated carrier interfacial transfer. However, the deliberate modulation of these interfacial chemical bonds remains a significant challenge. In this study, we successfully established a p-n junction composed of atomic-level Pt-doped CeO2 and 2D metalloporphyrins metal-organic framework nanosheets (Pt-CeO2/CuTCPP(Fe)), which enables the realization of photoelectric enhancement by regulating the interfacial Fe–O bond and optimizing the built-in electric field. Atomic-level Pt doping in CeO2 leads to an increased density of oxygen vacancies and lattice mutation, which induces a transition in interfacial Fe–O bonds from adsorbed oxygen (Fe–OA) to lattice oxygen (Fe–OL). This transition changes the interfacial charge flow pathway from Fe–OA–Ce to Fe–OL, effectively reducing the carrier transport distance along the atomic-level charge transport highway. This results in a 2.5-fold enhancement in photoelectric performance compared with the CeO2/CuTCPP(Fe). Furthermore, leveraging the peroxidase-like activity of the p-n junction, we employed this functional heterojunction interface to develop a photoelectrochemical immunoassay for the sensitive detection of prostate-specific antigens.

Treatment decision regret after precision prostatectomy: An analysis of patient-reported outcomes predicting decision regret.

This study aimed to assess postoperative decision regret (DR) after precision prostatectomy (PP), a novel subtotal surgical technique for prostate cancer (PCa) that involves the preservation of the unilateral capsule and seminal vesicle, and to identify factors predictive of DR after PP. After a shared decision-making process, 128 patients underwent PP for the treatment of localised PCa. Given the subtotal nature of the surgery, patients were informed about the possibility of a detectable prostate-specific antigen and secondary treatment. Between 6 and 12 months of follow-up, DR was analysed using the previously validated decision regret score (DRS). A univariable linear regression analysis was performed to analyse factors predictive of DR after PP. Between 6 and 12 months after PP, objective measurements of DR were obtained on 64 patients who completed the DRS. At the time of DRS, 16 patients were impotent (SHIM < 17), while six were incontinent (≥1 pad/day). The median time to DRS was 10months (IQR 7.5-11.8). Only two patients (3.1%) reported significant DR after PP (DRS > 25), while 53 patients (83%) reported no regret (DRS = 0). The median DRS was 0 (0-0). Incontinence and impotence at the time of DRS predicted higher DR after PP (incontinence estimate: 11.3 ± 3.2, p < 0.001; impotence estimate: 5.4 ± 2.3, p = 0.02). The incidence of DR after PP is low, with only 3% of patients reporting significant regret. Patients who are either incontinent or impotent after PP are more likely to regret their decision. Further studies with larger sizes and longer follow-ups are required to measure the longitudinal trends in DR after PP.

Integration of Immunosyringe Sensors with Bar-Chart Chips for Prick-and-Read Testing of Prostate Specific Antigen.

Pressure-based signal transduction is of promise in developing microfluidic immunoassays such as volumetric bar-chart chips (V-chips), but new working principles are required to further simplify the methods in point-of-care testing (POCT). Herein, we developed immunosyringe sensors and integrated them with bar-chart chips for simple prick-and-read testing of prostate specific antigen (PSA) as a model target. Disposable syringes served as the host for the construction of the sandwich-type immuno-recognition system. Platinum nanoparticles (Pt NPs) as the peroxidase-mimicking detection probe catalyzed the decomposition of H2O2 to produce O2 in the syringe cylinders, enabling the pressure-driven automatic injection of liquids from the syringes. The immuno-recognition event in the syringes was thereby converted into the quantitative autoinjection behavior of the syringes, namely, immunosyringe sensors. By simply pricking the sensors to bar-chart chips, we visually and quantitatively read the immunoassay signals as the bar-chart injection distance of liquids from the syringes in channels of the chips. The immunoassay showed a limit of detection (LOD) of 0.41 ng/mL in PSA detection with satisfactory accuracy in testing clinical serum samples. Owing to the integration with the immunosyringe sensors, this method, in comparison with conventional V-chips, works in a simpler prick-and-read manner without complex chip configurations and specialized chip operations (e.g., on-chip loading of microvolume reagents and sealing treatments). Therefore, the immunoassay shows great potential in POCT applications.

Construction and electrochemical performances of AuNPs functionalized bimetallic ZnCo-MOF derivatives and reduced graphene hybrid structure for highly sensitive prostate specific antigen detection

Construction and electrochemical performances of AuNPs functionalized bimetallic ZnCo-MOF derivatives and reduced graphene hybrid structure for highly sensitive prostate specific antigen detection

Polarization-independent ultra-sensitive graphene sensor for the detection of prostate-specific antigen

Polarization-independent ultra-sensitive graphene sensor for the detection of prostate-specific antigen

Real-Time and Ultrasensitive Prostate-Specific Antigen Sensing Using Love-Mode Surface Acoustic Wave Immunosensor Based on MoS2@Cu2O-Au Nanocomposites.

Prostate-specific antigen (PSA) is a well-established tumour marker for prostatic carcinoma. In this study, we present a novel, real-time, and ultrasensitive Love-mode surface acoustic wave (L-SAW) immunosensor for PSA detection enhanced by MoS2@Cu2O-Au nanocomposite conjugation. The MoS2@Cu2O-Au nanocomposites were analyzed by SEM, XRD, and EDS. The experiments show a significant improvement in sensitivity and detection limit compared with the previous detection methods utilizing nanogold alone to detect PSA biomolecules. The experimental results show a good linear relationship when the range of PSA concentrations between 200 pg/mL and 5 ng/mL was tested. The experimental results also show good specificity against alpha 1 fetoprotein and L-tryptophan disruptors.

Dual-site responsive module-triggered CRISPR/Cas12a switch with enhanced reaction kinetics for specific detection of PSA

Despite advances in DNA-based nanodevices for tumor biomarker detection, the pursuit of enhanced sensitivity and specificity remains a profound challenge. In this study, we designed an integrated dual-site responsive module as the AND logic gate that responded to both prostate-specific antigen (PSA) and apurinic/apyrimidinic endonuclease 1 (APE1), triggering a tetrahedral DNA nanostructure (TDN)-accelerated CRISPR/Cas12a signal switch for PSA detection. In detail, the dual-site responsive module was a T-shaped probe comprised of three DNA strands, which contained PSA aptamer and apurinic/apyrimidinic (AP) sites, significantly improving the specificity of prostate cancer screening by orthogonal recognition of PSA and APE1. When both PSA and APE1 were present, PSA could specifically bind with the aptamer, while APE1 catalyzed and cleaved the AP sites, releasing a part of one auxiliary strand as the mimic target (MT). To enhance the trans-cleavage efficiency of the CRISPR/Cas12a signal switch, we parallelly constructed the TDN with extended non-target strands (NTS) at each vertex, which could capture the MT to form double-stranded DNA (dsDNA) activators at the TDN vertices (TDN-activators) for triggering the CRISPR/Cas12a signal switch. Benefiting from the rigid framework of TDN, the TDN-activators not only increased the local concentration of Cas12a but also enabled a dominant conformation that was more favorable for recognizing and activating the Cas12a-crRNA complex, which demonstrated a 4.06-fold increase in trans-cleavage efficiency compared to that of dsDNA-activated Cas12a. This work applies the T-shaped probes and TDN-accelerated CRISPR/Cas12a signal switch to achieve the specific and sensitive electrochemiluminescence (ECL) detection of PSA from 1.0 × 10−5 to 10 μg/mL with a low limit of detection (LOD) of 4.5 × 10−6 μg/mL, offering a promising tool for early clinical screening of prostate cancer.

SERS-based CRISPR/Cas12a assays for protein biomarker prostate-specific antigen detection.

Sensitive and accurate detection of protein biomarkers is crucial for disease diagnosis, especially for early diagnosis. Here, we describe surface-enhanced Raman scattering (SERS)-based CRISPR/Cas12a assays (S-CRISPR) for protein biomarker detection. Firstly, an S-CRISPR-driven enzyme-linked immunosorbent assay (S-CasLISA) was developed utilizing a capture antibody coated on a microplate to recognize the target and a detection antibody labeled with active DNA to trigger the activity of CRISPR/Cas12a. With this assay, we achieved detection of prostate-specific antigen (PSA) as models at thepicogram level. The limit of detection (LoD) of S-CasLISA was 0.17pgmL-1 and in the range of 0.1pgmL-1 to 10ngmL-1. Further, we applied aptamer to S-CRISPR (S-Apt-CRISPR), combining the high sensitivity of SERS with the high selectivity of aptamers, while simplifying the operation process of CRISPR detection of protein biomarkers. The proposed S-Apt-CRISPR also could detect picogram-level PSA and without repeated washing steps. The LoD of S-Apt-CRISPR was 0.35pgmL-1 and in the range of 0.1pgmL-1 to 10ngmL-1.Both SERS-based CRISPR/Cas12a assays were validated with clinical samples and demonstrated accuracy consistent with the chemiluminescence immunoassay. The introduction of the CRISPR/Cas12a system with SERS has the effect of improving the analytical capabilities of the system, thereby broadening and facilitating its application in the analysis of sensitive and accurate protein biomarkers.

Functional Au@Cu/Cu2O/C composites derived from 2D Cu-based metal–organic framework for sensitive label-free electrochemical immunoassay

Metal-organic frameworks (MOFs) face challenges in electrochemical sensing due to low conductivity and poor stability. Herein, we report the synthesis of MOFs-derived metal/carbon composites (Au@Cu/Cu2O/C) that exhibit synergistic effects by combining metallic and carbonaceous characteristics due to their hierarchical structures and metal contents. The Au@Cu/Cu2O/C composites were characterized using electron microscopy, X-ray diffraction, Raman spectroscopy, and X-ray photoelectron spectroscopy. These composites inherit the exceptional properties of the pristine MOFs while exhibiting a large specific surface area, high electrical conductivity and stability. As an excellent electrode material, the Au@Cu/Cu2O/C composites were biofunctionalized with streptavidin and a biotinylated antibody for use as a highly sensitive, label-free electrochemical immunosensor for the detection of the tumor marker prostate specific antigen (PSA). The fabricated immunosensor successfully detected PSA concentrations ranging from 0.05 to 60 ng/mL, with a detection limit of 0.01 ng/mL, showcasing high sensitivity comparable to other existing methods. This research provides a versatile and promising platform for developing advanced biosensors for disease diagnostics and further expanding the application of MOFs.

Prostate-specific antigen, digital rectal examination, and prostate cancer detection: A study based on more than 7000 transrectal ultrasound-guided prostate biopsies in Ghana

Purpose of the studyThis study aims to determine the role of serum prostate-specific antigen (PSA) levels and digital rectal examination (DRE) in predicting the histological outcomes of prostate biopsies by analyzing a database of over 7000 patients who underwent transrectal ultrasound (TRUS)-guided prostate biopsies. MethodsWe conducted a retrospective analysis of men who underwent TRUS-guided prostate biopsies at Korle Bu Teaching Hospital, a tertiary referral center in Accra, Ghana, from July 2005 to December 2022. The biopsies, which included 10 to 12 core samples, were prompted by PSA levels greater than 4.0 ng/mL, abnormal DRE findings, or both. We then correlated histopathology results with PSA and DRE findings. ResultsOut of 7,338 patients who presented for biopsy, 76.3% were between the ages of 60 and 79. Histology reports were available for 5,289 patients, of whom 2,564 (48.5%) were diagnosed with prostate cancer. Cancer detection rates based on PSA levels were as follows: 21.6% for PSA <4 ng/mL, 21.7% for PSA 4-10 ng/mL, 32.7% for PSA 10-20 ng/mL, 53.0% for PSA 20-50 ng/mL, 71.5% for PSA 50-100 ng/mL, and 92.0% for PSA >100 ng/mL. When DRE findings were classified according to the 2016 TNM System (AJCC 8th Edition) as T1, T2, T3, and T4, cancer detection rates were 26.8%, 51.8%, 87.6%, and 95.7%, respectively. The overall cancer detection rate was significantly higher with abnormal DRE findings (64.6% vs. 26.7%, p < 0.001). Additionally, 78.2% of the detected cancers were high-grade (Gleason score of 7 or more). ConclusionThis extensive study of Ghanaian men undergoing TRUS biopsies reveals a high prostate cancer detection rate, with nearly 80% of the detected cancers being high-grade. These findings underscore the importance of PSA and DRE in the early detection of prostate cancer and should be considered in patient counseling and discussions regarding the implementation of prostate cancer screening programs in this population.

Better Oncological Outcomes After Prostate-specific Membrane Antigen Positron Emission Tomography–guided Salvage Radiotherapy Following Prostatectomy

Background and objectiveUp to 50% of patients with prostate cancer experience prostate-specific antigen (PSA) relapse following primary radical prostatectomy (RP). Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is increasingly being used for staging after RP owing to its high detection rate. Our aim was to compare outcomes for patients who received salvage radiotherapy (sRT) with versus without PSMA PET guidance. MethodsIn this observational case-control study, the control group consisted of 344 patients from the SAKK09/10 trial (sRT without PSMA PET guidance from 2011 to 2014). The treatment group consisted of 1548 patients from a retrospective multicenter cohort (PSMA PET-guided sRT from July 2013 to 2020). Data were collected up to November 2023. Patients with pN1 status at RP, initial cM1 status, cM1 status on PET, or PSA >0.5 ng/ml were excluded. Patients with detectable PSA after RP who were treated with sRT were eligible. We assessed 3-yr biochemical recurrence-free survival (BRFS) and metastasis-free survival (MFS). Key findings and limitationsThe study population of 717 patients comprised a control group (n = 255) with median follow-up of 75 mo and a PSMA PET group (n = 462) with median follow-up of 31 mo. In the PSMA PET cohort, 103 patients (22.3%) had PSMA-positive pelvic lymph nodes (PLNs), 85 (18.4%) received androgen deprivation therapy (ADT), and 104 (22.5%) underwent PLN irradiation. The BRFS rate at 3 yr was 71% (95% confidence interval [CI] 64–78%) for the control group and 77% (95% CI 72–82%) for the PSMA PET group. The PSMA PET group had favorable BRFS at 18–24 mo after sRT (hazard ratio 0.32, 95% CI 0.0.14–0.75; p = 0.01) and a lower rate of lymph node relapse after sRT (standardized mean difference 0.603). The MFS rate at 3 yr was 89.2% (95% CI 84.6–94.1%) for the control group and 91.2% (95% CI 88.1–94.4%) for the PSMA PET group. Conclusions and clinical implicationsOur results suggest a moderate improvement in short-term BRFS if PSMA PET is used to guide sRT. One possible reason is individualized PLN coverage facilitated by PET. MFS was not improved by PSMA PET guidance for sRT. Patients’ summaryFor patients who experience recurrence of prostate cancer after surgical removal of their prostate, salvage radiotherapy (sRT) is a further treatment option. We found that a type of scan called PSMA PET (prostate-specific membrane antigen positron emission tomography) to identify recurrence and guide sRT can improve recurrence-free survival because of better targeting of pelvic lymph nodes that may contain cancer cells.

Single‑center, retrospective, evaluator‑blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2‑miR‑H9/hsa‑miR‑3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zone.

Prostate-specific antigen (PSA) remains a key biomarker for the diagnosis and monitoring of prostate cancer (PCa). For patients within the 'PSA gray zone', the positive predictive value (PPV) of PSA for PCa detection by biopsy is estimated to be between 30 and 42%. In the present study, a single-center, retrospective, evaluator-blinded, pilot and pivotal clinical trial was performed to assess the clinical performance of the mirCaP kit (Urotech, Inc.), which measures the herpes simplex virus 2-microRNA (miR)-H9/hsa-miR-3659 ratio, with respect to helping physicians make appropriate decisions regarding further assessment of patients with PSA levels within this gray zone. For the patients in the initial clinical trial group who were in the PSA gray zone, the sensitivity, specificity, accuracy, PPV and negative predictive value (NPV) of the mirCaP kit were 94.29, 77.50, 85.33, 78.57 and 93.94%, respectively. For those in the pivotal clinical trial, these values were 94.50, 82.73, 87.90, 81.10 and 95.04%, respectively. These results suggest that the mirCaP kit may be an effective non-invasive diagnostic marker for PCa in patients with PSA levels in the gray zone. Thus, the mirCaP kit is a promising tool that can help physicians make a decision regarding the need for prostate biopsy in these patients. Of note, the NPV of >90% indicates that the mirCaP kit could prevent unnecessary prostate biopsies in >90% of these cases.

Factors affecting prostate cancer detection through asymptomatic PSA testing in primary care in England: Evidence from the 2018 National Cancer Diagnosis Audit.

Background Prostate-Specific Antigen (PSA) is used in primary care for prostate cancer detection, either for symptomatic assessment or asymptomatic testing following an informed decision. Aim To estimate the proportion of prostate cancer cases diagnosed following asymptomatic PSA testing, and patient and practice factors influencing this route. Design and setting 2018 English National Cancer Diagnosis Audit (NCDA) data were analysed, with linkage to the national cancer registry, practice-level Quality Outcomes Framework (QOF), and General Practice Patient Survey (GPPS) data. All 2018 NCDA patients with a diagnosis of prostate cancer were included (n = 9,837). Method Patients with recorded biomarker testing and no recorded symptoms prior to diagnosis were classified as asymptomatic PSA detected prostate cancer. Patient (age, ethnicity, deprivation, co-morbidities) and GP practice (geographical location, area deprivation, list size, urgent suspected cancer referral rate, QOF outcomes, GPPS results) factors were analysed for association with asymptomatic PSA testing using mixed effects logistic regression models. Results 1,884 out of 9,837 (19%) prostate cancer cases were detected following asymptomatic PSA testing, 982 (52.1%) of whom were patients aged 50-69 years. Younger age, non-White ethnicity, lower deprivation, and lower co-morbidity count were associated with an increased likelihood of diagnosis following asymptomatic PSA testing. There was a 13-fold variation between practices in the odds of asymptomatic PSA-detected cases, without clear explanatory GP practice-level factors. Conclusion One in five patients with prostate cancer in England are diagnosed after asymptomatic PSA testing in primary care, with large variation in asymptomatic PSA detection between GP practices.

An epitope imprinted electrochemical sensor for highly sensitive and selective determination of prostate-specific antigen.

Asimple method forhighly selective and sensitive prostate-specific antigen (PSA) detection using a molecularly imprinted electrochemical sensor ispresented. The sensor was developed through an epitope imprinted strategy combined with electrochemical measurement techniques. An epitope molecularly imprinted polymer (EMIP) film was constructed on a AuNPs-coated gold electrode surface through electropolymerization, utilizing the C-terminus epitope of PSA (KWIKDTIVANP) as the template molecular and o-phenylenediamine as the functional monomer. The characteristics of EMIP film were investigated by using a scanning electron microscope and electrochemical test methods, including electrochemical impedance spectroscopy and cyclic voltammetry. Key parameters such as electropolymerization cycles, elution and rebinding times, and the molar ratio of template molecular to functional monomer were systematically optimized. The sensor demonstrated a detection limit (LOD) of 0.31 fg/mL and exhibited an excellent linear response towards PSA concentration ranging from 1.0 fg/mL to 0.1 µg/mL. Furthermore, the EMIP sensor showed excellent selectivity against other biological macromolecules, such as bovine serum albumin, human serum albumin, alpha-fetoprotein, and carcinoembryonic antigen. With recoveriesbetween 95.89 and 106.04% for PSA detection in human serums theEMIP/AuNPs/AuE electrochemical sensor showed great potential in real sample analysis.